Effect of rabeprazole combined with anti-Helicobacter pylori in the treatment of gastric ulcer
雷贝拉唑联合抗幽门螺杆菌治疗胃溃疡的效果

摘要

目的 探究为胃溃疡患者应用雷贝拉唑联合抗幽门螺杆菌进行治疗所产生的效果。方法 从本院2013年12月到2021年11月收治胃溃疡患者中选取116例，将其随机分为对照组（58例，采用克拉霉素、甲硝唑、胶体果胶铋和奥美拉唑进行治疗）和研究组（58例，采用克拉霉素、阿莫西林、胶体果胶铋和雷贝拉唑进行治疗），对比两组临床总疗效、溃疡改善情况、炎症水平、HP根除率差异。结果 研究组用药总疗效高于对照组（P＜0.05）；研究组溃疡活动期、愈合期人数占比低于对照组，痊愈期人数占比高于对照组（P＜0.05）；溃疡面积小于对照组（P＜0.05），溃疡治疗前后差值大于对照组（P＜0.05）；研究组炎症水平低于对照组（P＜0.05）；研究组HP根除率高于对照组（P＜0.05）。结论 胃溃疡患者应用雷贝拉唑联合抗幽门螺杆菌治疗可提供更好的治疗效果，改善溃疡情况并降低炎症水平。

Abstract

Objective To explore the effect of rabeprazole combined with anti-Helicobacter pylori therapy on patients with gastric ulcer.
Methods 116 patients with gastric ulcers admitted to our hospital from December 2013 to November 2021 were randomly divided into a control group (58 cases treated with clarithromycin, metronidazole, colloidal bismuth pectin, and omeprazole) and a study group (58 cases treated with clarithromycin, amoxicillin, colloidal bismuth pectin, and rabeprazole). The clinical efficacy, ulcer improvement, inflammation level, and HP eradication rate of the two groups were compared and compared.
Results The total therapeutic effect of the observation group was higher than that of the control group (P<0.05); The proportion of active and healing ulcer patients in the observation group was lower than that in the control group, while the proportion of healing ulcer patients was higher than that in the control group (P<0.05); The ulcer area was smaller than that of the control group (P<0.05), and the difference before and after ulcer treatment was greater than that of the control group (P<0.05); The inflammation level in the observation group was lower than that in the control group (P<0.05); The HP eradication rate in the observation group was higher than that in the control group (P<0.05).
Conclusion   The use of rabeprazole combined with anti Helicobacter pylori treatment in patients with gastric ulcers can provide better therapeutic effects, improve ulcer conditions, and reduce inflammation levels.